NCT01576146View on ClinicalTrials.gov

Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 1, 2014

Study Completion Date

May 1, 2014

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

Etelcalcetide

Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.

Sponsors
All Listed Sponsors
lead

KAI Pharmaceuticals

INDUSTRY

NCT01576146 - Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism | Biotech Hunter | Biotech Hunter